Werkgroep Cardiologische centra Nederland

EMPEROR_HFrEF (Follow-up)

A phase III randomized, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with reduced Ejection Fraction (HFrEF).
Medicine
empagliflozin
Population
Heart failure
Phase
III
Starting year
2016
More information
ClinicalTrials.gov

Director of Study

dr. R.G.E.J. Groutars (Cardioloog)
Amsterdam, OLVG